Skip to main content
. 2023 Sep 29;13:16373. doi: 10.1038/s41598-023-43614-9

Table 2.

Medications used in this study.

Medications Total (n) Group C Group S
SGLT2i (n = 28)
 Empagliflozin 12 12
 Ipragliflozin 5 5
 Luseogliflozin 5 5
 Canagliflozin 3 3
 Tofogliflozin 3 3
ARB (n = 26)
 Telmisartan 9 3 6
 Olmesartan 7 4 3
 Candesartan 5 3 2
 Valsartan 3 1 2
 Irbesartan 2 2 0
ACEI (n = 2)
 Enarapril 2 1 1

SGLT2i sodium-glucose cotransporter 2 inhibitor, ARB angiotensin II type1 receptor blocker, ACEI angiotensin converting enzyme inhibitor.